Pembrolizumab for relapsed or refractory Hodgkin lymphoma - Author's reply
- PMID: 34087144
- DOI: 10.1016/S1470-2045(21)00290-4
Pembrolizumab for relapsed or refractory Hodgkin lymphoma - Author's reply
Conflict of interest statement
I have received honoraria from AbbVie, Bristol Myers Squibb, Amgen, AstraZeneca, Celgene, Gilead Sciences, Janssen, Karyopharm Therapeutics, Merck, Novartis, Roche, and Seattle Genetics; consultancy or advisory roles with AbbVie, Bristol Myers Squibb, Gilead Sciences, Karyopharm Therapeutics, Merck, Roche/Genentech, and Seattle Genetics; and have received research grants or funding from Janssen and Roche.
Comment on
-
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.Lancet Oncol. 2021 Apr;22(4):512-524. doi: 10.1016/S1470-2045(21)00005-X. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721562 Clinical Trial.
-
Pembrolizumab for relapsed or refractory Hodgkin lymphoma.Lancet Oncol. 2021 Jun;22(6):e234. doi: 10.1016/S1470-2045(21)00251-5. Lancet Oncol. 2021. PMID: 34087143 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
